Knopp Biosciences and Population Health Partners have created Areteia Therapeutics, a biopharmaceutical company.
Areteia’s main drug candidate is dexpramipexole, an oral eosinophil maturation inhibitor.
“Asthma is a common disease with a high unmet need and significant impact on the health and lives of millions of patients around the world,” said Jorge Bartolome, CEO of Areteia. “I am excited to partner with an expert team of drug developers to advance the first-ever oral treatment for eosinophilic asthma on behalf of these patients.”